首页 > 最新文献

Expert Review of Clinical Immunology最新文献

英文 中文
Molecular genotyping versus serological diagnosis for RH blood group typing in sickle cell patients. 镰状细胞患者 RH 血型分型的分子基因分型与血清学诊断。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-11-01 Epub Date: 2024-08-08 DOI: 10.1080/1744666X.2024.2388700
Zeinab Eftekhar, Arezoo Oodi, Naser Amirizadeh, Mahshid Mohammadipour, Bijan Keikhaei Dehdezi, Mohammad Ali Jalali Far

Objectives: High rate of alloimmunization in sickle cell disease (SCD) patients poses a significant challenge in finding compatible blood unit. Accurate determination of the blood group genotype of them can help reduce the alloimmunization risk. Tetra ARMS PCR is a novel method that has been utilized recently to investigate SNPs in diseases in a fast and reliable way.

Methods: Our study included 104 SCD and sickle thalassemia (Sβ) patients referred to Baghaei-2-Hospital of Ahvaz in 2019 using a nonrandom sampling method. Blood samples were collected for serological and molecular tests. Rh genotyping was performed using Tetra ARMS PCR and compared with the serological results.

Results: Based on the Tetra ARMS PCR method, out of 104 patients, 7 (6.7%) were d/d, 40 (38.5%) were D/d, 57 (54.8%) were D/D, 25 (24%) were C/C, 59 (56.7%) were C/c, 20 (19.3%) were c/c, 4 (3.8%) were E/E, 25 (24%) were E/e, and patients 75 (72.2%) were e/e. There were discrepancies in the serological and molecular results for 11 patients.

Conclusion: Use of Tetra ARMS PCR in combination with serological methods for determining the Rh blood group system in donors and transfusion-dependent patients represents a remarkable transformation in the field of immunohematology.

目的:镰状细胞病(SCD)患者的高同种免疫率给寻找相合的血液单位带来了巨大挑战。准确测定他们的血型基因型有助于降低同种免疫风险。Tetra ARMS PCR 是一种新型方法,最近已被用于快速、可靠地研究疾病中的 SNPs:我们的研究采用非随机抽样方法,纳入了 2019 年转诊至阿瓦士 Baghaei-2 医院的 104 名 SCD 和镰状地中海贫血(Sβ)患者。采集的血样用于血清学和分子检测。使用 Tetra ARMS PCR 进行 Rh 基因分型,并与血清学结果进行比较:根据 Tetra ARMS PCR 方法,104 名患者中,7 人(6.7%)为 d/d,40 人(38.5%)为 D/d,57 人(54.8%)为 D/D,25 人(24%)为 C/C,59 人(56.7%)为 C/c,20 人(19.3%)为 c/c,4 人(3.8%)为 E/E,25 人(24%)为 E/e,75 人(72.2%)为 e/e。11名患者的血清学和分子检测结果存在差异:结论:结合血清学方法使用 Tetra ARMS PCR 测定献血者和输血依赖患者的 Rh 血型,是免疫血液学领域的一次重大变革。
{"title":"Molecular genotyping versus serological diagnosis for RH blood group typing in sickle cell patients.","authors":"Zeinab Eftekhar, Arezoo Oodi, Naser Amirizadeh, Mahshid Mohammadipour, Bijan Keikhaei Dehdezi, Mohammad Ali Jalali Far","doi":"10.1080/1744666X.2024.2388700","DOIUrl":"10.1080/1744666X.2024.2388700","url":null,"abstract":"<p><strong>Objectives: </strong>High rate of alloimmunization in sickle cell disease (SCD) patients poses a significant challenge in finding compatible blood unit. Accurate determination of the blood group genotype of them can help reduce the alloimmunization risk. Tetra ARMS PCR is a novel method that has been utilized recently to investigate SNPs in diseases in a fast and reliable way.</p><p><strong>Methods: </strong>Our study included 104 SCD and sickle thalassemia (Sβ) patients referred to Baghaei-2-Hospital of Ahvaz in 2019 using a nonrandom sampling method. Blood samples were collected for serological and molecular tests. Rh genotyping was performed using Tetra ARMS PCR and compared with the serological results.</p><p><strong>Results: </strong>Based on the Tetra ARMS PCR method, out of 104 patients, 7 (6.7%) were d/d, 40 (38.5%) were D/d, 57 (54.8%) were D/D, 25 (24%) were C/C, 59 (56.7%) were C/c, 20 (19.3%) were c/c, 4 (3.8%) were E/E, 25 (24%) were E/e, and patients 75 (72.2%) were e/e. There were discrepancies in the serological and molecular results for 11 patients.</p><p><strong>Conclusion: </strong>Use of Tetra ARMS PCR in combination with serological methods for determining the Rh blood group system in donors and transfusion-dependent patients represents a remarkable transformation in the field of immunohematology.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1421-1426"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141893276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent insights into the impacts of COVID-19 on pediatric asthma. COVID-19 对小儿哮喘影响的最新见解。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-11-01 Epub Date: 2024-08-27 DOI: 10.1080/1744666X.2024.2390641
Carolina da Silva Alves, Raquel Baptista Pestana, Mário Morais-Almeida

Introduction: The emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the subsequent coronavirus disease 2019 (COVID-19) pandemic has raised questions about its impact on pediatric asthma. This review analyzes the latest research to offer a comprehensive understanding of the dynamics between COVID-19 and pediatric asthma.

Areas covered: This narrative review examines the effects of COVID-19 on pediatric asthma, exploring clinical outcomes, immune responses, recommended treatments, the impact of SARS-CoV-2 strains, and COVID-19 vaccination. Data were sourced from databases (PubMed, Embase, and BioRxiv/MedRxiv) from January 2020 to November 2023.

Expert opinion: In response to the COVID-19 pandemic, the international scientific community rapidly developed extensive knowledge, demonstrating unprecedented cooperation. Despite these advances, questions remain about SARS-CoV-2 infection and pediatric asthma. Most research consists of epidemiological studies with varying methods, sometimes yielding contradictory results. While asthma generally did not increase the risk of severe COVID-19 in children, uncontrolled asthma was a risk factor, highlighting the importance of maintaining asthma management. Telemedicine has proven effective for asthma control and will continue to grow, despite its limitations. Notably, allergic asthma may have a protective role against severe COVID-19. We recommend COVID-19 vaccination in the pediatric age group, including those with asthma.

导言:严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)的出现以及随后的冠状病毒病 2019(COVID-19)大流行引发了有关其对小儿哮喘影响的问题。本综述分析了最新研究,以全面了解 COVID-19 与小儿哮喘之间的动态关系:这篇叙述性综述研究了 COVID-19 对小儿哮喘的影响,探讨了临床结果、免疫反应、推荐治疗方法、SARS-CoV-2 株系的影响以及 COVID-19 疫苗接种。数据来源于2020年1月至2023年11月的数据库(PubMed、Embase和BioRxiv/MedRxiv):为应对 COVID-19 大流行,国际科学界迅速发展了广泛的知识,展现了前所未有的合作。尽管取得了这些进展,但有关 SARS-CoV-2 感染和小儿哮喘的问题依然存在。大多数研究都是流行病学研究,研究方法各不相同,有时会得出相互矛盾的结果。虽然哮喘一般不会增加儿童患严重 COVID-19 的风险,但不受控制的哮喘是一个风险因素,这突出了保持哮喘控制的重要性。远程医疗已被证明对哮喘控制有效,尽管有其局限性,但仍将继续发展。值得注意的是,过敏性哮喘可能对严重的 COVID-19 有保护作用。我们建议包括哮喘患者在内的儿童群体接种 COVID-19 疫苗。
{"title":"Recent insights into the impacts of COVID-19 on pediatric asthma.","authors":"Carolina da Silva Alves, Raquel Baptista Pestana, Mário Morais-Almeida","doi":"10.1080/1744666X.2024.2390641","DOIUrl":"10.1080/1744666X.2024.2390641","url":null,"abstract":"<p><strong>Introduction: </strong>The emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the subsequent coronavirus disease 2019 (COVID-19) pandemic has raised questions about its impact on pediatric asthma. This review analyzes the latest research to offer a comprehensive understanding of the dynamics between COVID-19 and pediatric asthma.</p><p><strong>Areas covered: </strong>This narrative review examines the effects of COVID-19 on pediatric asthma, exploring clinical outcomes, immune responses, recommended treatments, the impact of SARS-CoV-2 strains, and COVID-19 vaccination. Data were sourced from databases (PubMed, Embase, and BioRxiv/MedRxiv) from January 2020 to November 2023.</p><p><strong>Expert opinion: </strong>In response to the COVID-19 pandemic, the international scientific community rapidly developed extensive knowledge, demonstrating unprecedented cooperation. Despite these advances, questions remain about SARS-CoV-2 infection and pediatric asthma. Most research consists of epidemiological studies with varying methods, sometimes yielding contradictory results. While asthma generally did not increase the risk of severe COVID-19 in children, uncontrolled asthma was a risk factor, highlighting the importance of maintaining asthma management. Telemedicine has proven effective for asthma control and will continue to grow, despite its limitations. Notably, allergic asthma may have a protective role against severe COVID-19. We recommend COVID-19 vaccination in the pediatric age group, including those with asthma.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1347-1366"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prenatal heavy metal exposure and pediatric asthma, allergic rhinitis, atopic dermatitis: a systematic review and meta-analysis. 产前重金属暴露与小儿哮喘、过敏性鼻炎和特应性皮炎:系统回顾和荟萃分析。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-11-01 Epub Date: 2024-08-12 DOI: 10.1080/1744666X.2024.2390024
Xi Chen, Shipeng Zhang, Dongxi Jiang, Yu Li, Man Yin, Caishan Fang, Zeyi Lv, Yue Huang, Hao Yang, Hui Zhang, Jianfeng Zhang, Qinwei Fu, Hanyu Wang, Wenjing Jiang, Yang Chen, Xinrong Li

Objective: We review the prevalence of allergic diseases in children across prenatal exposures to heavy metals.

Methods: This systematic review and meta-analysis is registered in the PROSPERO database (CRD42023478471). A comprehensive search of PubMed, Web of Science, Medline and Cochrane library was conducted from the database inception until 31 October 2023. The Newcastle-Ottawa Quality Assessment Scale (NOS) was used to assess the quality of included studies. We used a random-effects model to summarize the effects from the studies.

Results: A total of 16 studies were included, 120,065 mother-child pairs enrolled. The NOS scores indicated that the quality of the literature included in the study was of a high standard.

Conclusion: The final results indicate that prenatal exposure to Pb increased the incidence of wheeze and Eczema in infants, and exposure to Ni and CD increased the incidence of AD in infants.

目的我们回顾了产前暴露于重金属的儿童过敏性疾病的发病率:本系统综述和荟萃分析已在 PROSPERO 数据库(CRD42023478471)中注册。从数据库建立到 2023 年 10 月 31 日,对 PubMed、Web of Science、Medline 和 Cochrane 图书馆进行了全面检索。采用纽卡斯尔-渥太华质量评估量表(NOS)评估纳入研究的质量。我们采用随机效应模型来总结研究的效果:共纳入 16 项研究,120,065 对母婴参加了研究。NOS评分表明,纳入研究的文献质量较高:最终结果表明,产前接触铅会增加婴儿喘息和湿疹的发病率,接触镍和CD会增加婴儿注意力缺失症的发病率。
{"title":"Prenatal heavy metal exposure and pediatric asthma, allergic rhinitis, atopic dermatitis: a systematic review and meta-analysis.","authors":"Xi Chen, Shipeng Zhang, Dongxi Jiang, Yu Li, Man Yin, Caishan Fang, Zeyi Lv, Yue Huang, Hao Yang, Hui Zhang, Jianfeng Zhang, Qinwei Fu, Hanyu Wang, Wenjing Jiang, Yang Chen, Xinrong Li","doi":"10.1080/1744666X.2024.2390024","DOIUrl":"10.1080/1744666X.2024.2390024","url":null,"abstract":"<p><strong>Objective: </strong>We review the prevalence of allergic diseases in children across prenatal exposures to heavy metals.</p><p><strong>Methods: </strong>This systematic review and meta-analysis is registered in the PROSPERO database (CRD42023478471). A comprehensive search of PubMed, Web of Science, Medline and Cochrane library was conducted from the database inception until 31 October 2023. The Newcastle-Ottawa Quality Assessment Scale (NOS) was used to assess the quality of included studies. We used a random-effects model to summarize the effects from the studies.</p><p><strong>Results: </strong>A total of 16 studies were included, 120,065 mother-child pairs enrolled. The NOS scores indicated that the quality of the literature included in the study was of a high standard.</p><p><strong>Conclusion: </strong>The final results indicate that prenatal exposure to Pb increased the incidence of wheeze and Eczema in infants, and exposure to Ni and CD increased the incidence of AD in infants.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1401-1409"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anakinra as first-line monotherapy for new-onset steroid-naïve sJIA patients. Anakinra 作为新发类固醇无效 sJIA 患者的一线单药疗法。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-30 DOI: 10.1080/1744666X.2024.2384703
Maria Vincenza Mastrolia, Sarah Abu-Rumeileh, Ilaria Maccora, Valerio Maniscalco, Edoardo Marrani, Ilaria Pagnini, Andrea Taddio, Gabriele Simonini
{"title":"Anakinra as first-line monotherapy for new-onset steroid-naïve sJIA patients.","authors":"Maria Vincenza Mastrolia, Sarah Abu-Rumeileh, Ilaria Maccora, Valerio Maniscalco, Edoardo Marrani, Ilaria Pagnini, Andrea Taddio, Gabriele Simonini","doi":"10.1080/1744666X.2024.2384703","DOIUrl":"10.1080/1744666X.2024.2384703","url":null,"abstract":"","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1293-1295"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transcriptomic observations of intra and extracellular immunotherapy targets for pediatric brain tumors. 小儿脑肿瘤细胞内和细胞外免疫疗法靶点的转录组观察。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-11-01 Epub Date: 2024-08-18 DOI: 10.1080/1744666X.2024.2390023
Stephen C Frederico, Itay Raphael, Michal Nisnboym, Sakibul Huq, Brent T Schlegel, Chaim T Sneiderman, Sydney A Jackson, Anya Jain, Michael R Olin, Brian R Rood, Ian F Pollack, Eugene I Hwang, Dhivyaa Rajasundaram, Gary Kohanbash

Objectives: Despite surgical resection, chemoradiation, and targeted therapy, brain tumors remain a leading cause of cancer-related death in children. Immunotherapy has shown some promise and is actively being investigated for treating childhood brain tumors. However, a critical step in advancing immunotherapy for these patients is to uncover targets that can be effectively translated into therapeutic interventions.

Methods: In this study, our team performed a transcriptomic analysis across pediatric brain tumor types to identify potential targets for immunotherapy. Additionally, we assessed components that may impact patient response to immunotherapy, including the expression of genes essential for antigen processing and presentation, inhibitory ligands and receptors, interferon signature, and overall predicted T cell infiltration.

Results: We observed distinct expression patterns across tumor types. These included elevated expression of antigen genes and antigen processing machinery in some tumor types while other tumors had elevated inhibitory checkpoint receptors, known to be associated with response to checkpoint inhibitor immunotherapy.

Conclusion: These findings suggest that pediatric brain tumors exhibit distinct potential for specific immunotherapies. We believe our findings can guide investigators in their assessment of appropriate immunotherapy classes and targets in pediatric brain tumors.

目标:尽管采取了手术切除、化学放疗和靶向治疗等方法,脑肿瘤仍然是导致儿童癌症相关死亡的主要原因。免疫疗法已显示出一定的前景,目前正在积极研究用于治疗儿童脑肿瘤。然而,为这些患者推进免疫疗法的一个关键步骤是发现可有效转化为治疗干预措施的靶点:在这项研究中,我们的团队对各种类型的儿童脑肿瘤进行了转录组分析,以确定免疫疗法的潜在靶点。此外,我们还评估了可能影响患者对免疫疗法反应的成分,包括抗原处理和递呈、抑制性配体和受体、干扰素特征以及总体预测的T细胞浸润所必需的基因的表达:结果:我们观察到不同肿瘤类型有不同的表达模式。结果:我们观察到不同肿瘤类型有不同的表达模式,包括一些肿瘤类型中抗原基因和抗原处理机制的表达升高,而另一些肿瘤中抑制性检查点受体的表达升高,已知这与检查点抑制剂免疫疗法的反应有关:这些发现表明,小儿脑肿瘤对特异性免疫疗法具有独特的潜力。我们相信,我们的研究结果可以指导研究人员评估小儿脑肿瘤的适当免疫疗法类别和靶点。
{"title":"Transcriptomic observations of intra and extracellular immunotherapy targets for pediatric brain tumors.","authors":"Stephen C Frederico, Itay Raphael, Michal Nisnboym, Sakibul Huq, Brent T Schlegel, Chaim T Sneiderman, Sydney A Jackson, Anya Jain, Michael R Olin, Brian R Rood, Ian F Pollack, Eugene I Hwang, Dhivyaa Rajasundaram, Gary Kohanbash","doi":"10.1080/1744666X.2024.2390023","DOIUrl":"10.1080/1744666X.2024.2390023","url":null,"abstract":"<p><strong>Objectives: </strong>Despite surgical resection, chemoradiation, and targeted therapy, brain tumors remain a leading cause of cancer-related death in children. Immunotherapy has shown some promise and is actively being investigated for treating childhood brain tumors. However, a critical step in advancing immunotherapy for these patients is to uncover targets that can be effectively translated into therapeutic interventions.</p><p><strong>Methods: </strong>In this study, our team performed a transcriptomic analysis across pediatric brain tumor types to identify potential targets for immunotherapy. Additionally, we assessed components that may impact patient response to immunotherapy, including the expression of genes essential for antigen processing and presentation, inhibitory ligands and receptors, interferon signature, and overall predicted T cell infiltration.</p><p><strong>Results: </strong>We observed distinct expression patterns across tumor types. These included elevated expression of antigen genes and antigen processing machinery in some tumor types while other tumors had elevated inhibitory checkpoint receptors, known to be associated with response to checkpoint inhibitor immunotherapy.</p><p><strong>Conclusion: </strong>These findings suggest that pediatric brain tumors exhibit distinct potential for specific immunotherapies. We believe our findings can guide investigators in their assessment of appropriate immunotherapy classes and targets in pediatric brain tumors.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1411-1420"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathogen-specific cell-mediated immunity to guide the management of cytomegalovirus in solid organ transplantation: state of the art clinical review. 病原体特异性细胞介导免疫指导实体器官移植中巨细胞病毒的管理:最新临床回顾。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-24 DOI: 10.1080/1744666X.2024.2384060
Raymund R Razonable

Introduction: Cytomegalovirus (CMV) is a common opportunistic infection after solid organ transplantation, with significant impact on morbidity and long-term survival. Despite advances in diagnostics and therapeutics, the management of CMV remains very challenging.

Areas covered: This article reviews emerging data on the clinical utility of laboratory assays that quantify cell-mediated immune responses to CMV. Observational studies have consistently demonstrated that a deficiency in pathogen-specific cell-mediated immunity is correlated with a heightened risk of primary, reactivation or recurrent CMV after transplantation. A limited number of interventional studies have recently investigated cell-mediated immune assays in guiding the prevention and treatment of CMV infection after solid organ transplantation.

Expert opinion: The pathogenesis and outcome of CMV after solid organ transplantion reflect the interplay between viral replication and CMV-specific immune reconstitution. Research in CMV-specific cell-mediated immunity paved way for the development of several laboratory assays that may assist clinicians in predicting the risk of CMV after transplantation, individualize the approach to CMV disease prevention, guide the need and duration of treatment of CMV infection, and predict the risk of relapse after treatment. More interventional studies are needed to further solidify the role of cell-mediated immune assays in various clinical situations after transplantation.

简介:巨细胞病毒(CMV)是实体器官移植后常见的机会性感染:巨细胞病毒(CMV)是实体器官移植后常见的机会性感染,对发病率和长期生存有重大影响。尽管在诊断和治疗方面取得了进步,但巨细胞病毒的管理仍然极具挑战性:这篇文章回顾了量化 CMV 细胞介导免疫反应的实验室检测方法的临床实用性的新数据。观察性研究一致表明,病原体特异性细胞介导免疫的缺乏与移植后原发性、再激活或复发性 CMV 风险的增加相关。最近,少数干预性研究对细胞介导免疫测定进行了调查,以指导预防和治疗实体器官移植后的 CMV 感染:专家观点:CMV 在实体器官移植后的发病机制和结局反映了病毒复制与 CMV 特异性免疫重建之间的相互作用。对CMV特异性细胞介导免疫的研究为多种实验室检测方法的开发铺平了道路,这些检测方法可帮助临床医生预测移植后CMV感染的风险、个性化的CMV疾病预防方法、指导CMV感染治疗的必要性和持续时间,以及预测治疗后复发的风险。要进一步巩固细胞介导免疫测定在移植后各种临床情况中的作用,还需要更多的介入性研究。
{"title":"Pathogen-specific cell-mediated immunity to guide the management of cytomegalovirus in solid organ transplantation: state of the art clinical review.","authors":"Raymund R Razonable","doi":"10.1080/1744666X.2024.2384060","DOIUrl":"10.1080/1744666X.2024.2384060","url":null,"abstract":"<p><strong>Introduction: </strong>Cytomegalovirus (CMV) is a common opportunistic infection after solid organ transplantation, with significant impact on morbidity and long-term survival. Despite advances in diagnostics and therapeutics, the management of CMV remains very challenging.</p><p><strong>Areas covered: </strong>This article reviews emerging data on the clinical utility of laboratory assays that quantify cell-mediated immune responses to CMV. Observational studies have consistently demonstrated that a deficiency in pathogen-specific cell-mediated immunity is correlated with a heightened risk of primary, reactivation or recurrent CMV after transplantation. A limited number of interventional studies have recently investigated cell-mediated immune assays in guiding the prevention and treatment of CMV infection after solid organ transplantation.</p><p><strong>Expert opinion: </strong>The pathogenesis and outcome of CMV after solid organ transplantion reflect the interplay between viral replication and CMV-specific immune reconstitution. Research in CMV-specific cell-mediated immunity paved way for the development of several laboratory assays that may assist clinicians in predicting the risk of CMV after transplantation, individualize the approach to CMV disease prevention, guide the need and duration of treatment of CMV infection, and predict the risk of relapse after treatment. More interventional studies are needed to further solidify the role of cell-mediated immune assays in various clinical situations after transplantation.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1367-1380"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies. 脊柱关节炎和银屑病关节炎的治疗争议:聚焦生物制剂和靶向疗法。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-29 DOI: 10.1080/1744666X.2024.2384705
Fadi Kharouf, Dafna D Gladman

Introduction: There are several treatment controversies that have emerged in spondyloarthritis and psoriatic arthritis. These are related to the nature of the conditions as well as to the use of medications.

Areas covered: This review, which included a search of PubMed database as well as the references within the articles provides an overview of the nature of spondyloarthritis, controversy over the inclusion of psoriatic arthritis (PsA) as a peripheral spondyloarthritis, and a summary of current treatments for both PsA and axial spondyloarthritis (axSpA), with special emphasis on targeted therapy. The review highlights the differences in response to certain medications, particularly biologic therapy and summarizes the randomized controlled trials in psoriatic arthritis and axial spondyloarthritis providing data about the responses in table format.

Expert opinion: There is a need for better outcome measures in axSpA. Currently, the measures are subjective. Imaging may be more appropriate but there is a need for research into the reliability and responsiveness of imaging techniques. In PsA, there may also be better response measures and research into the reliability and responsiveness of available measures is underway. There is also a need for novel therapies as well as biomarkers for response in both diseases.

导言:脊柱关节炎和银屑病关节炎在治疗方面出现了一些争议。这些争议与疾病的性质以及药物的使用有关:这篇综述包括对 PubMed 数据库的检索以及文章中的参考文献,概述了脊柱关节炎的性质、将银屑病关节炎 (PsA) 作为外周脊柱关节炎的争议、PsA 和轴性脊柱关节炎 (axSpA) 目前的治疗方法,并特别强调了靶向治疗。综述强调了对某些药物(尤其是生物疗法)反应的差异,并总结了银屑病关节炎和轴性脊柱关节炎的随机对照试验,以表格形式提供了有关反应的数据:轴性脊柱关节炎需要更好的疗效衡量标准。目前,衡量标准都是主观的。成像可能更合适,但需要对成像技术的可靠性和响应性进行研究。对于 PsA,也可能有更好的反应测量方法,目前正在对现有测量方法的可靠性和反应性进行研究。此外,这两种疾病都需要新型疗法和反应生物标志物。
{"title":"Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies.","authors":"Fadi Kharouf, Dafna D Gladman","doi":"10.1080/1744666X.2024.2384705","DOIUrl":"10.1080/1744666X.2024.2384705","url":null,"abstract":"<p><strong>Introduction: </strong>There are several treatment controversies that have emerged in spondyloarthritis and psoriatic arthritis. These are related to the nature of the conditions as well as to the use of medications.</p><p><strong>Areas covered: </strong>This review, which included a search of PubMed database as well as the references within the articles provides an overview of the nature of spondyloarthritis, controversy over the inclusion of psoriatic arthritis (PsA) as a peripheral spondyloarthritis, and a summary of current treatments for both PsA and axial spondyloarthritis (axSpA), with special emphasis on targeted therapy. The review highlights the differences in response to certain medications, particularly biologic therapy and summarizes the randomized controlled trials in psoriatic arthritis and axial spondyloarthritis providing data about the responses in table format.</p><p><strong>Expert opinion: </strong>There is a need for better outcome measures in axSpA. Currently, the measures are subjective. Imaging may be more appropriate but there is a need for research into the reliability and responsiveness of imaging techniques. In PsA, there may also be better response measures and research into the reliability and responsiveness of available measures is underway. There is also a need for novel therapies as well as biomarkers for response in both diseases.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1381-1400"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epstein-Barr virus-driven lymphoproliferation in inborn errors of immunity: a diagnostic and therapeutic challenge. 先天性免疫错误中由 Epstein-Barr 病毒驱动的淋巴细胞增殖:诊断和治疗的挑战。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-30 DOI: 10.1080/1744666X.2024.2386427
Prabal Barman, Suprit Basu, Taru Goyal, Saniya Sharma, Sangeetha Siniah, Rahul Tyagi, Kaushal Sharma, Ankur K Jindal, Rakesh K Pilania, Pandiarajan Vignesh, Manpreet Dhaliwal, Deepti Suri, Amit Rawat, Surjit Singh

Introduction: Inborn errors of immunity (IEI) are a group of genetically heterogeneous disorders with a wide-ranging clinical phenotype, varying from increased predisposition to infections to dysregulation of the immune system, including autoimmune phenomena, autoinflammatory disorders, lymphoproliferation, and malignancy. Lymphoproliferative disorder (LPD) in IEI refers to the nodal or extra-nodal and persistent or recurrent clonal or non-clonal proliferation of lymphoid cells in the clinical context of an inherited immunodeficiency or immune dysregulation. The Epstein-Barr virus (EBV) plays a significant role in the etiopathogenesis of LPD in IEIs. In patients with specific IEIs, lack of immune surveillance can lead to an uninhibited proliferation of EBV-infected cells that may result in chronic active EBV infection, hemophagocytic lymphohistiocytosis, and LPD, particularly lymphomas.

Areas covered: We intend to discuss the pathogenesis, diagnosis, and treatment modalities directed toward EBV-associated LPD in patients with distinct IEIs.

Expert opinion: EBV-driven lymphoproliferation in IEIs presents a diagnostic and therapeutic problem that necessitates a comprehensive understanding of host-pathogen interactions, immune dysregulation, and personalized treatment approaches. A multidisciplinary approach involving immunologists, hematologists, infectious disease specialists, and geneticists is paramount to addressing the diagnostic and therapeutic challenges posed by this intriguing yet formidable clinical entity.

导言:先天性免疫错误(IEI)是一组遗传异质性疾病,其临床表型多种多样,从感染易感性增加到免疫系统失调,包括自身免疫现象、自身炎症性疾病、淋巴细胞增生和恶性肿瘤。IEI 中的淋巴细胞增生性疾病(LPD)是指在遗传性免疫缺陷或免疫失调的临床背景下,淋巴细胞结节性或结节外、持续性或复发性克隆性或非克隆性增生。Epstein-Barr 病毒(EBV)在 IEIs 的 LPD 发病机制中起着重要作用。在特定的 IEIs 患者中,免疫监视的缺乏会导致 EBV 感染细胞不受抑制地增殖,从而可能导致慢性活动性 EBV 感染、嗜血细胞性淋巴组织细胞增多症和 LPD,尤其是淋巴瘤:我们将讨论不同 IEI 患者中 EBV 相关 LPD 的发病机制、诊断和治疗方法:EBV驱动的IEIs淋巴细胞增生是一个诊断和治疗问题,需要全面了解宿主与病原体的相互作用、免疫失调和个性化治疗方法。免疫学家、血液学家、传染病专家和遗传学家共同参与的多学科方法对于解决这一有趣而又可怕的临床实体所带来的诊断和治疗难题至关重要。
{"title":"Epstein-Barr virus-driven lymphoproliferation in inborn errors of immunity: a diagnostic and therapeutic challenge.","authors":"Prabal Barman, Suprit Basu, Taru Goyal, Saniya Sharma, Sangeetha Siniah, Rahul Tyagi, Kaushal Sharma, Ankur K Jindal, Rakesh K Pilania, Pandiarajan Vignesh, Manpreet Dhaliwal, Deepti Suri, Amit Rawat, Surjit Singh","doi":"10.1080/1744666X.2024.2386427","DOIUrl":"10.1080/1744666X.2024.2386427","url":null,"abstract":"<p><strong>Introduction: </strong>Inborn errors of immunity (IEI) are a group of genetically heterogeneous disorders with a wide-ranging clinical phenotype, varying from increased predisposition to infections to dysregulation of the immune system, including autoimmune phenomena, autoinflammatory disorders, lymphoproliferation, and malignancy. Lymphoproliferative disorder (LPD) in IEI refers to the nodal or extra-nodal and persistent or recurrent clonal or non-clonal proliferation of lymphoid cells in the clinical context of an inherited immunodeficiency or immune dysregulation. The Epstein-Barr virus (EBV) plays a significant role in the etiopathogenesis of LPD in IEIs. In patients with specific IEIs, lack of immune surveillance can lead to an uninhibited proliferation of EBV-infected cells that may result in chronic active EBV infection, hemophagocytic lymphohistiocytosis, and LPD, particularly lymphomas.</p><p><strong>Areas covered: </strong>We intend to discuss the pathogenesis, diagnosis, and treatment modalities directed toward EBV-associated LPD in patients with distinct IEIs.</p><p><strong>Expert opinion: </strong>EBV-driven lymphoproliferation in IEIs presents a diagnostic and therapeutic problem that necessitates a comprehensive understanding of host-pathogen interactions, immune dysregulation, and personalized treatment approaches. A multidisciplinary approach involving immunologists, hematologists, infectious disease specialists, and geneticists is paramount to addressing the diagnostic and therapeutic challenges posed by this intriguing yet formidable clinical entity.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1331-1346"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141765859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aleukemic variant of T-cell large granular lymphocyte leukemia in patients with rheumatoid arthritis - diagnostically challenging subtype. 类风湿性关节炎患者中的 T 细胞大颗粒淋巴细胞白血病 Aleukemic 变异型--诊断上具有挑战性的亚型。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-24 DOI: 10.1080/1744666X.2024.2384057
Vadim Gorodetskiy, Andrey Sudarikov

Introduction: The typical clinical manifestations of T-cell large granular lymphocyte (T-LGL) leukemia are an increase in the number of large granular lymphocytes (LGLs) in the blood > 2000 cells/μL, neutropenia, and splenomegaly. In rare cases of so-called 'aleukemic' T-LGL leukemia, the number of LGLs is <400-500 cells/μL. In patients with rheumatoid arthritis (RA), distinguishing T-LGL leukemia with low tumor burden in the blood and bone marrow from Felty syndrome (FS) poses diagnostic challenges.

Areas covered: This review aimed to describe the basic characteristics and variants of aleukemic T-LGL leukemia, with a special focus on aleukemic T-LGL leukemia with massive splenomegaly (splenic variant of T-LGL leukemia) and differential diagnosis of such cases with hepatosplenic T-cell lymphoma. The significance of mutations in the signal transducer and activator of transcription 3 (STAT3) gene for distinguishing aleukemic RA-associated T-LGL leukemia from FS is discussed, along with the evolution of the T-LGL leukemia diagnostic criteria. PubMed database was used to search for the most relevant literature.

Expert opinion: Evaluation of STAT3 mutations in the blood and bone marrow using next-generation sequencing, as well as a comprehensive spleen study, may be necessary to establish a diagnosis of aleukemic RA-associated T-LGL leukemia.

导读:T细胞大颗粒淋巴细胞(T-LGL)白血病的典型临床表现是血液中大颗粒淋巴细胞(LGL)数量增加T细胞大颗粒淋巴细胞(T-LGL)白血病的典型临床表现是血液中大颗粒淋巴细胞(LGL)数量增加,大于2000个/μL,中性粒细胞减少,脾脏肿大。在极少数所谓的 "白血病 "T-LGL白血病病例中,大颗粒淋巴细胞的数量被覆盖:本综述旨在描述白血病型T-LGL白血病的基本特征和变异型,特别关注伴有脾脏大量肿大的白血病型T-LGL白血病(T-LGL白血病脾脏变异型),以及此类病例与肝脾T细胞淋巴瘤的鉴别诊断。本文讨论了信号转导和转录激活因子3(STAT3)基因突变对区分白血病RA相关T-LGL白血病和FS的意义,以及T-LGL白血病诊断标准的演变。PubMed数据库用于搜索最相关的文献:专家观点:要确诊白血病RA相关T-LGL白血病,可能需要使用新一代测序技术评估血液和骨髓中的STAT3突变,并进行全面的脾脏研究。
{"title":"Aleukemic variant of T-cell large granular lymphocyte leukemia in patients with rheumatoid arthritis - diagnostically challenging subtype.","authors":"Vadim Gorodetskiy, Andrey Sudarikov","doi":"10.1080/1744666X.2024.2384057","DOIUrl":"10.1080/1744666X.2024.2384057","url":null,"abstract":"<p><strong>Introduction: </strong>The typical clinical manifestations of T-cell large granular lymphocyte (T-LGL) leukemia are an increase in the number of large granular lymphocytes (LGLs) in the blood > 2000 cells/μL, neutropenia, and splenomegaly. In rare cases of so-called 'aleukemic' T-LGL leukemia, the number of LGLs is <400-500 cells/μL. In patients with rheumatoid arthritis (RA), distinguishing T-LGL leukemia with low tumor burden in the blood and bone marrow from Felty syndrome (FS) poses diagnostic challenges.</p><p><strong>Areas covered: </strong>This review aimed to describe the basic characteristics and variants of aleukemic T-LGL leukemia, with a special focus on aleukemic T-LGL leukemia with massive splenomegaly (splenic variant of T-LGL leukemia) and differential diagnosis of such cases with hepatosplenic T-cell lymphoma. The significance of mutations in the signal transducer and activator of transcription 3 (<i>STAT3</i>) gene for distinguishing aleukemic RA-associated T-LGL leukemia from FS is discussed, along with the evolution of the T-LGL leukemia diagnostic criteria. PubMed database was used to search for the most relevant literature.</p><p><strong>Expert opinion: </strong>Evaluation of <i>STAT3</i> mutations in the blood and bone marrow using next-generation sequencing, as well as a comprehensive spleen study, may be necessary to establish a diagnosis of aleukemic RA-associated T-LGL leukemia.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1323-1330"},"PeriodicalIF":3.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Conventional and new immunotherapies for immune system dysregulation in postpartum mood disorders: comparisons to immune system dysregulations in bipolar disorder, major depression, and postpartum autoimmune thyroid disease. 治疗产后情绪障碍免疫系统失调的传统和新型免疫疗法:与双相情感障碍、重度抑郁症和产后自身免疫性甲状腺疾病的免疫系统失调进行比较。
IF 3.9 3区 医学 Q2 IMMUNOLOGY Pub Date : 2024-10-29 DOI: 10.1080/1744666X.2024.2420053
Hemmo A Drexhage, Veerle Bergink, Sara Poletti, Francesco Benedetti, Lauren M Osborne

Introduction: Postpartum mood disorders are heterogenous disorders and comprise postpartum psychosis and postpartum depression. Evidence is accumulating that systemic monocyte/macrophage activation, low-grade inflammation and (premature senescence related) T cell defects increase the risk for mood disorders outside pregnancy by affecting the function of microglia and T cells in the emotional brain (the cortico-limbic system) leading to inadequate mood regulation upon stress.

Areas covered: The evidence in the literature that similar immune dysregulations are present in postpartum mood disorders.

Results: The physiological postpartum period is characterized by a rapid T cell surge and a mild activation of the monocyte/macrophage system. Postpartum mood disorder patients show a diminished T cell surge (including that of T regulatory cells) and an increase in low grade inflammation, that is, an increased inflammatory state of monocytes/macrophages and higher levels of serum pro-inflammatory cytokines.

Expert opinion: Anti-inflammatory agents (e.g. COX-2 inhibitors) and T cell boosting agents (e.g. low-dose IL-2 therapy) should be further investigated as treatment. The hypothesis should be investigated that postpartum mood disorders are active episodes (triggered by changes in the postpartum immuno-endocrine milieu) in ongoing, dynamically fluctuating aberrant neuro-immune-endocrine trajectories leading to mood disorders in women (inheritably) vulnerable to these disorders.

简介产后情绪障碍是一种异质性疾病,包括产后精神病和产后抑郁症。越来越多的证据表明,全身性单核细胞/巨噬细胞活化、低度炎症和(与早衰有关的)T细胞缺陷会影响情绪脑(皮质-边缘系统)中小胶质细胞和T细胞的功能,导致应激时情绪调节功能不足,从而增加妊娠外情绪失调的风险:文献证据表明,产后情绪失调也存在类似的免疫失调:产后生理期的特点是 T 细胞迅速激增和单核细胞/巨噬细胞系统轻度激活。产后情绪障碍患者的 T 细胞激增(包括 T 调节细胞的激增)减弱,低度炎症增加,即单核细胞/巨噬细胞的炎症状态增加,血清促炎细胞因子水平升高:专家意见:应进一步研究抗炎药物(如 COX-2 抑制剂)和 T 细胞促进剂(如小剂量 IL-2 治疗)的治疗方法。专家意见:应进一步研究抗炎药物(如 COX-2 抑制剂)和 T 细胞促进剂(如低剂量 IL-2 治疗)作为治疗手段的假设,即产后情绪失调是持续、动态波动的异常神经-免疫-内分泌轨迹中的活跃事件(由产后免疫-内分泌环境变化引发),导致易患情绪失调的妇女(遗传性)患上情绪失调。
{"title":"Conventional and new immunotherapies for immune system dysregulation in postpartum mood disorders: comparisons to immune system dysregulations in bipolar disorder, major depression, and postpartum autoimmune thyroid disease.","authors":"Hemmo A Drexhage, Veerle Bergink, Sara Poletti, Francesco Benedetti, Lauren M Osborne","doi":"10.1080/1744666X.2024.2420053","DOIUrl":"10.1080/1744666X.2024.2420053","url":null,"abstract":"<p><strong>Introduction: </strong>Postpartum mood disorders are heterogenous disorders and comprise postpartum psychosis and postpartum depression. Evidence is accumulating that systemic monocyte/macrophage activation, low-grade inflammation and (premature senescence related) T cell defects increase the risk for mood disorders outside pregnancy by affecting the function of microglia and T cells in the emotional brain (the cortico-limbic system) leading to inadequate mood regulation upon stress.</p><p><strong>Areas covered: </strong>The evidence in the literature that similar immune dysregulations are present in postpartum mood disorders.</p><p><strong>Results: </strong>The physiological postpartum period is characterized by a rapid T cell surge and a mild activation of the monocyte/macrophage system. Postpartum mood disorder patients show a diminished T cell surge (including that of T regulatory cells) and an increase in low grade inflammation, that is, an increased inflammatory state of monocytes/macrophages and higher levels of serum pro-inflammatory cytokines.</p><p><strong>Expert opinion: </strong>Anti-inflammatory agents (e.g. COX-2 inhibitors) and T cell boosting agents (e.g. low-dose IL-2 therapy) should be further investigated as treatment. The hypothesis should be investigated that postpartum mood disorders are active episodes (triggered by changes in the postpartum immuno-endocrine milieu) in ongoing, dynamically fluctuating aberrant neuro-immune-endocrine trajectories leading to mood disorders in women (inheritably) vulnerable to these disorders.</p>","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-23"},"PeriodicalIF":3.9,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Expert Review of Clinical Immunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1